Clinical trial · Expanded Access
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
NCT00994916CI-TRIAL-00039391no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lambert-Eaton Myasthenic Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3,4 diaminopyridine | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosis of LEMS 2. Over 18 years old 3. Medically stable 4. If female and premenopausal, have a negative urine pregnancy test prior to starting the 3,4 DAP, and, if premenopausal, be willing to practice an effective form of birth control such as "double-barrier contraception" during the study Exclusion Criteria: 1. Known sensitivity to 3,4 DAP 2. History of past or current seizures 3. History of severe asthma 4. Believed by the investigator to be unable to comply with the protocol 5. Unable to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.